7 best EDC platforms for hepatology and liver disease trials in 2026

A hepatology protocol rarely holds still. As noninvasive biomarkers take over from liver biopsy and imaging endpoints get refined mid-study, every amendment either moves through your electronic data capture (EDC) system in days or stalls enrollment while you wait on a vendor programmer. Viedoc's EDC software is built for that movement, with a no-code Designer that lets your team push mid-study changes without a change-control queue. This comparison reviews seven EDC platforms against amendment velocity, lab and imaging flexibility, no-code configuration, and compliance breadth.

You're running a program where liver function panels, transient elastography readings, and central imaging reads all have to reconcile with your case report forms before a data manager can even open a query. Every amendment, whether it's a new MRI-PDFF threshold or an added biomarker panel, has to move through your EDC without downtime, and your team needs to make those changes itself, not wait behind other sponsors' studies in a queue.

Enterprise EDC platforms built for large, late-phase oncology trials often over-engineer this problem, requiring dedicated programmers and change-control cycles that stretch amendment turnaround well beyond what a lab panel update should take. Budget or academic-oriented tools rarely carry the audit trail depth a regulated program needs. The platforms below were evaluated on how well they balance regulatory rigor with the flexibility hepatology protocols demand.

Best EDC solutions for hepatology and liver disease trials: quick comparison

These seven EDC platforms represent the most evaluated options for hepatology and liver disease programs, reviewed across build speed, data flexibility, and compliance.

1. Viedoc

Viedoc's EDC software is designed for studies where the case report form keeps changing, not just the ones where it's fixed at go-live. Data managers configure and launch electronic case report forms (eCRFs), edit checks, and workflows through Viedoc Designer with no coding required, and mid-study updates deploy without downtime. The platform has powered more than 8,000 global studies, with a 100% FDA inspection pass rate across those studies.

For a hepatology program juggling central lab panels, imaging reads, and patient-reported symptom diaries, having EDC, ePRO software, and randomization and trial supply management (RTSM) on one platform removes the reconciliation work a fragmented eClinical stack creates. Viedoc's open application programming interface (API) and Clinical Data Interchange Standards Consortium (CDISC)-compliant formats connect directly to labs, registries, and clinical trial management system (CTMS) platforms, so imaging and lab results sync automatically. Certified designer training means your own team can own the build, rather than routing every amendment through a vendor queue.

Viedoc EDC is compliant with FDA 21 CFR Part 11, ICH GCP, GDPR, and HIPAA, and is ISO 27001 and SOC 2 certified, with 99.99% platform uptime on Microsoft Azure. The Viedoc Inspection Readiness Packet (VIRP) gives your QA team structured audit-readiness documentation ahead of an inspection, and support is available 24/7. For hepatology programs running across the US, Europe, and Japan, the platform's coverage of 75-plus countries and 40-plus languages keeps site-level data collection consistent wherever enrollment happens.

Khadija B., an enterprise data manager, described her experience this way. "Data capturing has been made easy because of Viedoc, it is incredibly robust and easy to navigate."

• Study scale: 8,000+ global studies, with a 100% FDA inspection pass rate
• Build speed: Self-service study builds can go live in as little as one day; professional-services builds typically complete in 8 to 12 weeks
• Uptime: 99.99% platform uptime, hosted on Microsoft Azure
• Compliance: FDA 21 CFR Part 11, ICH GCP, GDPR, and HIPAA; ISO 27001 and SOC 2 certified
• Inspection readiness: Viedoc Inspection Readiness Packet (VIRP) available to all customers
• Pricing: Unlimited user seats, no per-user fees, transparent study-based licensing
  
  
  

  Launch, manage, and monitor clinical trials faster with intuitive EDC clinical trial software that keeps you compliant and audit ready.

2. Medidata

Medidata offers Rave EDC, an electronic data capture platform for capturing, managing, cleaning, and reporting site-, patient-, and lab-reported clinical trial data. The platform supports protocol amendments and mid-study changes without downtime, letting study teams deploy updates to a live study without a lengthy migration process. Rave EDC integrates with the wider Medidata Platform, connecting to modules including eCOA, RTSM, and Clinical Data Studio, and Rave Companion lets sites populate forms directly from electronic health record data rather than re-entering it manually. For smaller or early-phase studies, Medidata also offers Rave Lite, a streamlined version of Rave built for Phase I, Phase IV, and MedTech post-market trials.

3. Veeva

Veeva EDC is part of the Veeva Clinical Platform, providing an environment for designing case report forms and collecting site-reported patient data, local lab results, DICOM images, and medical coding. Case report forms are built through an in-product specification studio, and protocol amendments deploy with no downtime, an operational benefit for studies with changing biomarker or imaging endpoints. Veeva EDC also includes role-based interfaces intended to speed source data verification and medical review, and it is built to handle multi-arm adaptive trial designs without requiring custom functions. As part of the broader Veeva Clinical Platform, Veeva EDC connects to Veeva's RTSM, CTMS, and eTMF applications, and Veeva Connections are designed to automate data transfer between these applications rather than requiring manual reconciliation.

4. Castor EDC

Castor EDC is a cloud-based, API-driven electronic data capture platform that integrates study data from electronic health records, case report forms, ePRO and eCOA sources, laboratory systems, and wearables into a single environment. Case report forms are built through a low-code builder, and Castor reports that low-complexity studies can be deployed in as little as three to four weeks. The platform includes live dashboards for tracking enrollment and site performance, and it supports 21 CFR Part 11 and HIPAA-aligned workflows. Castor also offers eConsent and ePRO modules that run on the same database as its EDC, and it operates across more than 90 countries.

5. Medrio

Medrio provides a CDMS/EDC platform built for small and scaling clinical teams, combining electronic data capture with data validation, query management, audit trails, and database lock in one system. Studies are built through a no-code, point-and-click builder, and the platform supports both online and offline data capture for sites without reliable internet access. Medrio states that studies deploy across more than 30 countries and that mid-study form and logic changes can be tested in an always-on validation environment before going live, without data migration or extended downtime. The platform is compliant with FDA 21 CFR Part 11, ICH E6(R2), HIPAA, and GDPR, and it supports MedTech, biotech, pharmaceutical, and CRO organizations from early feasibility through post-marketing studies.

6. Oracle Life Sciences

Oracle Life Sciences Clinical One Data Collection is a cloud-based data collection platform built on Oracle Cloud Infrastructure, unifying electronic data capture with data from electronic health records, laboratory feeds, wearable sensors, and patient applications in a single environment. Oracle states that studies can be built in weeks rather than months, with mid-study changes deployed in real time without a lengthy migration process. Clinical One Data Collection connects to Oracle's Clinical One randomization and trial supply management module for coordinated study setup, and Oracle also maintains its legacy InForm EDC system for sponsors on established Oracle Clinical deployments. Oracle Life Sciences has been positioned as a Leader in the Everest Group PEAK Matrix assessment for electronic data capture products.

7. Zelta by Merative

Zelta by Merative is a cloud-based electronic data capture platform with eCOA, medical coding, and local lab management built directly into the system rather than layered on as separate modules. Merative states Zelta has hosted more than 4,500 clinical trials across all phases, including over 500 Phase III trials in 23 therapeutic areas, with data collection supported in more than 100 countries and over 75 languages and dialects. The platform includes a point-and-click EDC designer and supervised machine learning to assist with CDASH-based medical coding, alongside real-time edit checks intended to reduce data queries. Mid-study updates are designed to deploy with minimal disruption to sites and participants.

What to look for in EDC solutions for hepatology and liver disease trials

Central lab and imaging data integration depth

Hepatology endpoints increasingly rely on non-invasive markers rather than biopsy alone, so your EDC needs to pull structured data from central labs and imaging vendors, not just capture what a site types into a form. The platform's API and CDISC-compliant formats determine whether results sync automatically or get manually re-keyed at every visit.

Best-in-class platforms expose a REST API or connector service that ingests central lab and imaging feeds directly into the eCRF, with edit checks that flag out-of-range biomarker values as they arrive. Manual reconciliation is a common source of query backlog in hepatology protocols, and it compounds every time the biomarker panel changes.

Amendment velocity for evolving biomarker endpoints

Hepatology protocols amend more often than most therapeutic areas as biomarker thresholds get refined mid-study, so the real test of an EDC platform isn't how fast the initial build goes live, it's how fast a data manager can push a change without vendor downtime.

Best-in-class platforms let a certified in-house designer deploy a mid-study amendment in hours to days, without the database going offline or subject data being re-migrated. A protocol that adds a second imaging read six months into enrollment shouldn't cost a change-control cycle measured in weeks.

No-code versus programmer-dependent configuration

A platform that requires a vendor-side programmer for every form change puts your team at the mercy of someone else's ticket queue, a liability where lab panels and imaging protocols are still maturing.

Look for a drag-and-drop or point-and-click study designer your own certified staff can operate, with training governance that scales designer capacity as your portfolio grows rather than depending on a single vendor contact.

Multi-region compliance and language coverage

Hepatology programs, particularly NASH, MASH, and viral hepatitis studies, increasingly enroll across the US, Europe, and Asia-Pacific to hit target populations fast enough, which means your EDC needs to satisfy FDA, EMA, and regional data protection requirements at once, not just the sponsor's home jurisdiction.

Best-in-class platforms carry ISO 27001 and SOC 2 certification alongside GDPR, HIPAA, and 21 CFR Part 11 compliance, and support enough languages that sites in different regions can each work in their own language.

Support infrastructure and escalation pathways

When a site raises a data query outside your team's working hours, the support model, not the feature list, determines whether that query gets resolved before the next monitoring visit.

Best-in-class vendors offer 24/7 support with clear escalation pathways for QA and IT, rather than a single regional help desk covering every time zone.

How to choose the right EDC solution for hepatology and liver disease trials

Step 1: Define your biomarker and imaging data strategy

Map out whether your program will lean on liver biopsy, non-invasive biomarkers such as transient elastography or MRI-PDFF, or a mix that shifts over the study, since this determines how much integration depth your EDC needs. A platform overbuilt for a biopsy-only design and underbuilt for an imaging-heavy one costs you either way.

Step 2: Assess how many mid-study amendments your protocol design implies

A dose-ranging study with a fixed endpoint amends far less than an adaptive trial where biomarker thresholds are still being validated, so match amendment turnaround to your actual protocol volatility, not a generic industry average.

Step 3: Evaluate integration depth with your specific lab and imaging vendors

Ask each shortlisted vendor to demonstrate, not describe, how their API or connector ingests data from the central lab and imaging providers your program uses, since a general "open API" claim doesn't guarantee your specific vendors are supported.

Step 4: Scrutinize the vendor's track record with comparably complex protocols

A platform proven on straightforward single-endpoint trials may not hold up under a protocol with layered biomarker panels, so ask for evidence of amendment turnaround and data quality on comparably complex studies, not just overall study count.

Step 5: Choose a platform sized to your program and your team's build capacity

If your team wants to own the build in-house rather than depend on a vendor programmer, Viedoc's EDC software is built for that, with a no-code Designer and transparent per-study licensing. A demo focused on your biomarker and imaging integration needs is the fastest way to see whether it fits.

Frequently asked questions

What is the best EDC platform for hepatology and liver disease trials?

Viedoc's EDC software is the strongest fit for most hepatology and liver disease programs, thanks to a no-code Designer that lets in-house data managers push amendments without vendor delays, an open API connecting lab and imaging data into the eCRF, and compliance spanning FDA 21 CFR Part 11, GDPR, and HIPAA across 75-plus countries. Medidata's Rave EDC suits large, late-phase programs already standardized on the wider Medidata Platform. Castor EDC suits smaller, lower-complexity studies wanting a self-service, no-code build.

What should I look for when choosing an EDC platform for hepatology trials?

Prioritize amendment velocity, integration depth with your central lab and imaging vendors, no-code configuration so your own team can own the build, and compliance across every enrollment region. Hepatology protocols change more than most therapeutic areas as biomarker thresholds mature, so a platform that treats amendments as routine saves the most time over a multi-year study.

How long does it take to build and deploy a hepatology study database?

Timelines vary by platform and complexity, but most modern EDC vendors report self-service builds ranging from a few days to several weeks for lower-complexity studies, with professional-services-led builds for complex, multi-region protocols typically running 8 to 12 weeks. What matters most for hepatology programs is not initial build time but how quickly the platform absorbs an amendment once biomarker or imaging endpoints get refined.

What compliance certifications should I look for in an EDC platform for a global hepatology program?

Look for FDA 21 CFR Part 11 compliance for electronic records and signatures, ICH GCP alignment, GDPR coverage for EU enrollment, and HIPAA attestation for US patient data. ISO 27001 and SOC 2 certification indicate independently audited security controls, which matters more in programs routing sensitive liver function and imaging data through the platform's API.

How does Viedoc's study build and amendment speed compare to Medidata's?

Viedoc's EDC software offers self-service builds live in as little as one day, with professional-services-led builds typically completing in 8 to 12 weeks, and mid-study updates deployed by your own certified data managers through Viedoc Designer. Medidata's own site states that Rave EDC supports amendments and mid-study changes with no downtime once a change is built, and offers AI-assisted setup tools to reduce configuration time. For sponsors wanting their own team configuring changes directly rather than through a dedicated study builder role, that distinction in ownership is often the more practical difference between the two platforms.

Which EDC platforms support imaging and lab-heavy hepatology trial designs?

Platforms with an open API or connector service built for lab, imaging, and EHR integration suit biomarker-heavy hepatology protocols best. Viedoc's EDC software connects to labs, registries, and imaging vendors through a REST API and CDISC-compliant formats, while Oracle's Clinical One Data Collection and Zelta by Merative both position their platforms around unifying data from multiple external sources. Ask for a live demonstration with your specific vendors rather than relying on a general API claim.

Making the right EDC choice for hepatology and liver disease trials

The eClinical software market is estimated at more than $11 billion in 2025 and growing at roughly 14% annually, and the platforms above span that market, from suite-first enterprise incumbents to modular, EDC-first vendors built for faster-moving mid-market programs. What they share is a baseline of 21 CFR Part 11 and GDPR-aligned compliance; where they differ is how much programming they require and how quickly they absorb a mid-study change.

Match your choice to your program's actual profile. A large, late-phase trial already embedded in an enterprise eClinical ecosystem may reasonably stay with a suite incumbent, while a growth-stage sponsor running an adaptive, biomarker-driven Phase II program typically gets more value from a modular, no-code platform its own team can operate. US teams tend to weight build speed and return on investment most heavily, while EMEA and APAC teams typically weight compliance credentials and vendor stability higher, so factor your primary enrollment geography into the decision, not just your headquarters.

Switching EDC vendors mid-program carries real validation cost, so the platform you choose at study start is the one your team lives with through database lock, which makes amendment agility worth weighing as heavily as initial build speed.

Why Viedoc is the best EDC choice for hepatology and liver disease trials

If your hepatology program needs an EDC platform that keeps pace with evolving biomarker and imaging endpoints, Viedoc's EDC software is built for exactly that. Studies have gone live in as little as one day for self-service builds, and the platform has supported more than 8,000 global studies with a 100% FDA inspection pass rate.

Viedoc Designer puts study configuration in your team's hands, with no vendor programmer required and no per-user fees as your program scales into new sites. Add 24/7 support, Certified Designer Training, and a modular suite covering ePRO, RTSM, and electronic trial master file (eTMF) management alongside EDC, and your team gets one platform instead of a stitched-together eClinical stack.

Viedoc is ISO 27001 and SOC 2 certified, compliant with FDA 21 CFR Part 11, ICH GCP, GDPR, and HIPAA, and the Viedoc Inspection Readiness Packet gives your QA team structured documentation ahead of an inspection. Founded in 2003 in Uppsala, Sweden, Viedoc has built more than two decades of experience supporting regulated research across 75-plus countries.

If you want to see how Viedoc's EDC software would handle your specific biomarker panels and imaging integrations, book a demo or request a proposal and our team will walk through study build speed, compliance credentials, and module depth in the context of your own hepatology program.